Biohaven Pharmaceutical Holding Company Ltd. (BHVN) |
|
26.01 0 (0%)
|
09-29 16:00 |
|
Open: |
26.32 |
Pre. Close: |
26.01 |
|
High:
|
27.4 |
Low:
|
25.65 |
|
Volume:
|
2,493,651 |
Market Cap:
|
1,777(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:10 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 32 One year: 37.37 |
| Support: |
Support1: 20.63 Support2: 16.45 |
| Resistance: |
Resistance1: 27.39 Resistance2: 32 |
| Pivot: |
19.56 |
| Moving Average: |
MA(5): 22.08 MA(20): 19.32
MA(100): 20.37 MA(250): 17.01 |
| MACD: |
MACD(12,26): 0.8 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 88.2 %D(3): 68 |
| RSI: |
RSI(14): 75.4 |
| 52-week: |
High: 27.39 Low: 5.53 |
| Average Vol(K): |
3-Month: 1,006 (K) 10-Days: 1,517 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BHVN ] has closed It is unclear right now based on current values. 130.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
27.42 - 27.56 |
27.56 - 27.65 |
|
Low:
|
25.33 - 25.51 |
25.51 - 25.62 |
|
Close:
|
25.76 - 26.02 |
26.02 - 26.19 |
|
Company Description |
|
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut. |
Headline News |
Wed, 20 Sep 2023
Biohaven Ltd. Receives Positive Ratings and Investor Interest ... - Best Stocks
Sat, 19 Aug 2023
Barclays PLC reduces holdings in Biohaven Ltd., while Director ... - Best Stocks
Mon, 31 Jul 2023
Biohaven Reports Second Quarter 2023 Financial Results and ... - PR Newswire
Mon, 17 Jul 2023
Cantor Fitzgerald Reiterates Biohaven (BHVN) Overweight ... - Nasdaq
Thu, 01 Jun 2023
BHVN Stock Exits 'Stealth Mode' And Hits A Record High - Investor's Business Daily
Thu, 23 Mar 2023
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
68 (M) |
| Shares Float |
51 (M) |
|
% Held by Insiders
|
14.4 (%) |
|
% Held by Institutions
|
100.9 (%) |
|
Shares Short
|
5,250 (K) |
|
Shares Short P.Month
|
4,900 (K) |
Stock Financials |
|
EPS
|
-6.35 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-87.8 |
|
Return on Equity (ttm)
|
-209 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-293 (M) |
|
Levered Free Cash Flow
|
-179 (M) |
Stock Valuations |
|
PE Ratio
|
-4.1 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.58 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.07 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
